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Three first-in-human clinical trials using Sleeping Beauty (SB)
transposition for immunotherapy of T cells expressing a CD19-spe-
cific chimeric antigen receptor (CAR) have received institutional and
federal regulatory approvals and are under way at the University of
TexasMDAndersonCancerCenter. To understand potential risks in-
volved in using non-viral SB transposition to genetically modify clin-
ical-grade T cells, we employed high-throughput sequencing
(Illumina) and profiling (BlueBioU supercomputer at Rice University)
of the SB-mediatedCAR insertion sites inT cells. Our SB clinical vec-
tor inserted 99.999% of the time at expected TA dinucleotide sites,
with 39% of the insertions localizing to intragenic loci and 61%map-
ping to intergenic regions. The vast majority (96.5%) of intragenic in-
sertions are intronic while the majority (.60%) of intergenic
transpositions fall within non-coding repeat regions. By linkingmicro-
array gene expression and vector insertion profiles, we observed that
CAR insertions favor conformationally ‘‘open’’ transcriptional start
sites (TSS). The integration profiles for SB-modified T cells compare
favorably to T cells transduced with recombinant retrovirus (RV): 1)
there are less insertions within intragenic regions (39% SB vs. 56%
RV), 2) insertions concentrated at GC-poor regions (gene-poor re-
gions SB vs. gene-rich regions RV), 3) TSS associated with quiescent
T cells were favored (reflecting the electro-transfer of SB DNA plas-
mids into quiescent non-proliferating T cells vs. retroviral transduc-
tion of activated T cells), 4) no bias in insertions into potentially
dangerous loci (e.g. oncogene, tumor suppressor, miRNA etc.). In
the absence of targeted insertions by clinical vectors, the next best op-
tion to assess safety of any gene insertion is validating a randompattern
of integrations with an evenly-distributed insertion profile across the
whole genome to minimize hot spot and potentially deleterious clonal
expansion of therapeuticT cells.We now seek to proactively profile, in
a time-sensitive manner, the integration events of T-cell products
prior to infusion to provide clinicians with a statement regarding the
randomness of transgene integration to allow data-driven decisions
as whether to proceed with infusion of our genetically modified prod-
ucts. Ourmethods and findings are consistent with the therapeutic po-
tential for human application of SB system.44
FACTORS CONTRIBUTING TO VIRAL INFECTIONS AND THE LIMITED EF-
FICACY OF ADOPTIVELY TRANSFERRED DONOR DERIVED IMMUNODO-
MINANT VIRUS-SPECIFIC T-CELLS IN RECIPIENTS OF HAPLOIDENTICAL
STEM CELL TRANSPLANTS
Hasan, A.N., Doubrovina, E., Barnett, L., Prockop, S., O’Reilly, R.J.Me-
morial Sloan-Kettering Cancer Center, New York, NY
HLA haplotype-disparate transplants are increasingly used for the
treatment of patients lacking a matched donor. The high morbidity
and mortality from serious viral infections (specifically CMV) has
limited the success of this transplant approach. Despite success
with adoptive immunotherapy for post transplant viral infections, se-
lected recipients of haplotype disparate transplants fail to respond to
adoptively transferred virus-specific donor TC.
TC sensitized in-vitro against protein usually respond to 1-2 immu-
nodominant epitopes presented by specific donor HLA alleles. We
questioned (1) how often CMV-specific T cells (CMV-CTL) from
an HLA-haplotype disparate donor were restricted by donor-unique
alleles, since such TC would be inactive against virus-infected host
cells, and (2) which epitopes induced more robust anti-viral responses.
Accordingly, we tested CMV-CTL responses from 11 CMV seropos-
itive HLA haplotype disparate donors, and 6 patients. TC were sensi-tized over 21-28 days with CMVpp65 peptide loaded autologous DC.
Epitopes eliciting IFNg [+] TCweremapped using amatrix of peptide
pools, and their HLA-restriction determined.
Six of 11 donors tested responded to CMV epitopes presented by
HLA alleles shared with the recipient, while 5 responded exclusively
to epitopes presented by donor-unique HLA alleles. Patients receiv-
ing transplants from the latter 5 donors experienced prolongedCMV
viremia, CMV chorioretinitis and/or pneumonitis. CMV-CTL iso-
lated from each of the six patients over 1 year post HSCT were spe-
cific for epitopes presented byHLA alleles shared by their donors. In
patients transplanted fromdonors whoseCMV-CTLwere restricted
by donor-unique HLA alleles, the engrafted TC responded to an
epitope that was different from the donor CMV-CTL, but restricted
by an HLA allele shared with the donor, suggesting that these TC
may have developed from donor precursors differentiating in the
host thymus. In general, responses against epitopes presented by
HLA C0401, B3501 and A0101were less robust.
Overall, in a significant proportion of cases (5/11), CMV-CTL
from HLA haplotype disparate donors are restricted by donor-
unique HLA alleles, and the development of effective CMV-specific
responses in the patient is delayed until the evolution of new TC
from host thymic precursors. These data can be used to predict
CMV infections and develop adoptive immunotherapy strategies
to overcome infectious mortality in haploidentical transplants.45
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We have demonstrated that small numbers of ex vivo-expanded,
trivirus T cells, targeting EBV, CMV, and Adv are safe, proliferate in
vivo and protect against all 3 viruses post-HSCT. However, broader
implementation is limited by the need for infectious virus (EBV), clin-
ical adenovector, and prolonged (6 wk) manufacture. In addition, com-
petition between viral antigens limits extension to other viruses.We are
now evaluating whether infusion of rapidly-generated donor trivirus T
cells (rCTL), stimulated only once with DCs nucleofected with DNA
plasmids encoding immunogenic EBV (LMP2, EBNA1, BZLF1), Adv
(Hexon, Penton), and CMV (pp65, IE1) antigens, and expanded in the
presence of IL4+7 in a gas permeable device (G-Rex), is safe and sim-
ilarly effective in HSCT recipients with active infections.
WithNHLBI-PACT support, 18 clinical rCTL lines have been gen-
erated.From15x106PBMCs,wepreparedamedianof241.6x106 rCTLs
(range100-420x106) in9-12days.The rCTLswerepolyclonal, compris-
ing both CD4 (31615%) and CD8 (62617%) cells, with specificity for
CMV (IE1: 360636; pp65: 697629 SFC/2x105), EBV (LMP2:
222613, EBNA1: 90611 and BZLF1: 1216910) and Adv (Hexon:
286619, Penton: 206613), and no evidence of alloreactivity against re-
cipient cells (median 0% sp. release, 20:1 E:T). We have treated 3 pa-
tients on DL1 (5x106/m2) of this phase I/II study with no adverse
events. Patients 1 and 2 received rCTL for CMV reactivation. In Pt1,
low grade CMV reactivation (100 copies/ml) resolved upon infusion.
This patient also had detectable Adv in blood that resolved. Clearance
of both viruses corresponded with an increase in detectable CMV and
Adv-specificT cells in peripheral blood (PB). Four weeks later Pt1 again
reactivatedCMV(increase from0 to.10,000copies/ml)while receiving
antivirals.Concurrently the frequencyofCMV-reactiveTcells increased
from12 to528SFC/4x105 andpeakTcell reactivity correlatedwith viral
clearance. Pt 2 was similarly able to clear CMV (1500 copies/ml) with
a corresponding increase (from 0 to 96 and 0 to 51 SFC/4x105) in both
IE1 and pp65-specific T cells, respectively. The 3rd patient received
rCTL for Adv and is too early to evaluate. Infusion of rCTLs has thus
been safe to date and is associated with the appearance of virus-specific
cells in PB and subsequent virus clearance. We are now extending this
platform to additional viruses, thereby broadening the spectrumof path-
ogens that can be targeted with a single T cell line.S219
